Cancer is diagnosed today much too late: increasing sensitivity by thousand folds, Akrivis’ Z-TECT technology will allow cancer detection so early that it will be cured faster and with less toxic drugs. Z-TECT can achieve this with blood tests or medical imaging of mm-sized tumors. After selling custom reagents to repeat customers for a year, Akrivis recently signed a worldwide distribution agreement and seeks $250k to hire 2 scientists and accelerate the launch of its first products by Q1 2013

2012 Boston Silver Winner